Elzovantinib is under clinical development by Turning Point Therapeutics and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According to GlobalData, Phase II drugs for Metastatic Hepatocellular Carcinoma (HCC) have a 23% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Elzovantinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Elzovantinib overview

Elzovantinib (TPX-0022) is under development for the treatment of advanced solid tumors including hepatocellular carcinoma, colorectal cancer, gastric cancer, non-small cell lung cancer, gastroesophageal (GE) junction carcinomas, metastatic brain tumor, central nervous system tumor, adenocarcinoma of the gastroesophageal junction, metastatic hepatocellular carcinoma (HCC), metastatic colorectal cancer and unspecified cancer. The drug candidate is a new chemical entity. The drug candidate is administered through oral route in the form of tablet. It acts by inhibiting CSF1R, SRC and MET.

Turning Point Therapeutics overview

Turning Point Therapeutics (TP therapeutics) is a biopharmaceutical company. It designs and develops clinical stage small molecule, targeted oncology therapies to address key limitations of existing lung cancer therapies. Its pipeline products include Repotrectinib, macrocyclic tyrosine kinase inhibitor, TPX-0022, multi-targeted kinase inhibitor, TPX-0046, a multi-targeted orally bioavailable TKI, TPX – 013 and ALK inhibitor. TP therapeutics also provides clinical trial activities such as TRIDENT-1 and compassionate use programs. The company’s macrocyclic platform addresses the issues of emerging treatment resistance and toxicities that limit duration of treatment. It operates in the US and Switzerland. TP Therapeutics is headquartered in San Diego, California, the US.

For a complete picture of Elzovantinib’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.